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Abstract 
The enzyme thimet oligopeptidease (TOP) catalyzes the hydrolysis of gonadotropin-releasing 
hormone (GnRH) in vitro, and evidence suggests that TOP is the primary enzyme responsible for 
GnRH hydrolysis in vivo, as well.  If this is true, TOP could play an important role in regulating 
steroid hormone production via the hypothalamic-pituitary-gonadal (HPG) axis.  In addition to 
its function at the level of the hypothalamus, TOP may also have a direct effect at the target 
tissue level.  In order to determine if TOP has a direct modulating effect androgen and estrogen 
functions, prostate cancer cells were treated with estradiol, an end product of the HPG axis.  If 
TOP and steroid hormones comprise a feedback loop, treatment with estradiol could regulate 
TOP levels, localization or activity.  After estradiol treatment, TOP staining was imaged 
confocally in prostate cancer cells.  TOP was also detected and quantified in cell lysates by 
immunoblot.  Quantification of TOP staining in prostate cancer cell images suggested that 
estradiol treatment increased cellular TOP levels and also increased nuclear TOP levels in 
particular.  However, Western analysis showed that overall TOP levels varied very little with 
estradiol treatment.  Although not definitive, these results indicate that TOP responds differently 
with direct treatment of prostate cancer cells by estradiol as compared to estradiol treatment 
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Nomenclature 
 
ER  estrogen receptor 
FSH  follicle-stimulating hormone 
GnRH   gonadotropin-releasing hormone 
HPG axis  hypothalamic-pituitary-gonadal axis 
ICC   immunocytochemistry 
JA-2   N-[1-(R, S)-carboxy-3-phenylpropyl]-Ala-Aib-Tyr-p-aminobenzoate 
LH   luteinizing hormone 
PEP   prolyl endopeptidase 
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Introduction 
 
The enzyme thimet oligopeptidase (TOP, EC 3.4.24.15, EP24.15) is present in most 
tissues of the human body.  It catalyzes the hydrolysis of many short peptides, as long as they 
fulfill certain general restrictions.  Many of the peptides it cleaves happen to be integral to 
important biological processes.  One of its many substrates is gonadotropin-releasing hormone 
(GnRH), levels of which control the amounts of estrogens and androgens the body produces.  
Although the circumstances under which TOP degrades GnRH in the body are not well known, it 
certainly seems likely that this degradation could directly affect systemic estrogen and androgen 
levels.  Androgens and estrogens have enormous influence on human reproductive function and 
behavior, and abnormal production of these hormones contributes to many diseases.  If it is true 
that TOP has influence in the production of androgens and estrogens, TOP could be an important 
component in the process of human reproductive regulation. 
 
Thimet Oligopeptidase (TOP) 
TOP is a soluble, 75kDa enzyme first isolated from rat brain, and is part of a family of 
zinc metalloendopeptidases that also includes angiotensin-converting enzyme, neprilysin, 
neurolysin, and thermolysin1-3.  Human TOP was purified from erythrocytes in 1993, and has 
properties very similar to rat and chicken TOP4.  Highest TOP activity is found in the brain, 
testes, and anterior and posterior pituitary, with lower activity in most other tissues, including 
spleen, liver, kidney, lung, adrenal glands, and thyroid5.  In rat brain, TOP is found 
predominantly in the nuclei of neural and glial cells6,7.  However, in a study that examined 
localization in the mouse pituitary tumor cell line ATt20, TOP was found at high levels in the 
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cytoplasm, and was also secreted8.  TOP is also present in plasma membranes of ATt20 cells, 
including on the extracellular surface9.  Overall, TOP is found in most tissues of the body, and on 
a cellular level, within the nucleus, cytoplasm, cell membrane and extracellular space.   
TOP cleaves peptides that range in size from 8 to 17 amino acids long, preferentially at a 
bond on the carboxyl side of hydrophobic residues10.  Its substrates include GnRH, neurotensin, 
somatostatin, endothelin, bradykinin, enkephalin precursors and nociceptin10,11.  Thus TOP has 
been studied in relation to physiological pathways that incorporate these neuropeptides, 
including reproduction, blood pressure regulation and nociception12.  TOP also cleaves amyloid 
precursor protein similarly to the action of beta-secretase, creating amyloid fragments13,14.  TOP 
cleaves GnRH, a decapeptide, at the Tyr5-Gly6 bond10 (Fig. 1).  TOP can be phosphorylated by 
cAMP-dependent protein kinase (PKA) at Serine 644, which alters its kinetic parameters towards 
GnRH, but not towards those of most of its other substrates.  Phosphorylated TOP has both a 
greater KM and kcat, indicating that GnRH is less likely to move into the active site, but that when 
it does it is turned over more quickly.  Tullai et al. suggest that this may help TOP handle sudden 
increases in GnRH concentration during pulsatile release15. 
 
 
Figure 1.  TOP and prolyl endopeptidase cleavage sites in GnRH.  Prolyl endopeptidase 
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TOP in the Hypothalamic-Pituitary-Gonadal (HPG) Axis 
The HPG axis controls development and reproduction through the production of 
androgens and estrogens.  The median eminence of the hypothalamus releases GnRH in a 
pulsatile manner, which is transported through the hypophyseal portal system to the pituitary 
gland16,17.  The binding of GnRH to receptors on the secretory cells of the anterior pituitary 
signals them to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH)18.  LH 
and FSH travel through the bloodstream to the gonads.  In females LH and FSH signal the 
ovaries to release estrogen, and stimulate follicle maturation and ovulation.  In males, LH signals 
the testes to produce testosterone, and FSH initiates spermatogenesis.  The final products of this 
system, estrogen, testosterone, and dihidrotestosterone (the activated form of testosterone), all 
act at the levels of both the pituitary and hypothalamus in a negative feedback loop to reduce 
production of LH, FSH and GnRH19.   
TOP certainly cleaves GnRH in vitro, but this alone does not guarantee that TOP has any 
effect on the HPG axis or on steroid hormone regulation.  TOP itself hydrolyzes GnRH too 
slowly to effectively degrade GnRH in vivo, but Lew et al. found that the enzyme prolyl 
endopeptidase (prolyl oligopeptidase, POP, PEP, EC3.4.21.26) enhances TOP’s degradation of 
GnRH by removing the C-terminal glycinamide, thus increasing its affinity for TOP (Fig. 1)20.  
Prolyl endopeptidase is found in all tissues, with especially high levels in the brain, available for 
use in GnRH degradation21, and PEP and TOP are coexpressed in cells of the ventromedial 
nucleus of the hypothalamus22.  PEP levels in the region are also down-regulated in parallel with 
TOP, which suggests that TOP, with the help of PEP, could indeed be acting on GnRH in the 
hypothalamus22.  However, in order to cleave GnRH and have an effect on the HPG axis, TOP 
must be present in the extracellular space.  TOP is both secreted and located on the extracellular 
	   9 
surface of cells, which should allow it access to secreted GnRH23.  In support of the theory that 
TOP cleaves GnRH in the brain, Lasdun et al. found that intracerebroventricular injection of 
GnRH and a TOP inhibitor into rat brain resulted in high recovery of GnRH – indicating less 
GnRH was degraded than if only GnRH were injected.  In contrast, injection of inhibitors of two 
other endopeptidases suspected of cleaving GnRH did not change the amount of GnRH 
degraded24.  Wu et al. found TOP present in the region of the median eminence of rat 
hypothalamus where GnRH axons terminate near the hypophyseal portal vessels, further 
suggesting that TOP is in a position to cleave GnRH.  They also measured TOP activity to be 
three times greater in the hypophyseal portal blood than in peripheral blood.  They induced an 
LH surge in female rats, and found that when TOP was inhibited, LH serum concentration was 
higher than in rats with no inhibitor, which could imply more GnRH was being produced as a 
result of TOP’s inhibition25. 
 Pierotti et al. studied TOP levels in the tissues of the HPG axis with respect to 
reproductive development.  They found that TOP levels increased in the hypothalamus, anterior 
pituitary, ovaries and testes during the development of male and female rats.  After puberty, TOP 
activity increased to a maximum in the preoptic area of the hypothalamus of males and females, 
and declined gradually afterward.  In the anterior pituitary, TOP activity decreased after puberty 
and plateau-ed.  In the ovaries, TOP activity rose during puberty, but returned to pre-pubertal 
levels afterward.  However in the testes, TOP activity steadily rose during development to reach 
an activity at adulthood at least three times greater than in any other tissue26.  These fluctuations 
in TOP activity suggest that it may be involved in reproductive regulation.  
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Estradiol regulation of TOP 
One way to determine whether TOP might be involved in regulation of steroid hormones 
through the HPG axis is to test whether it is involved in a feedback mechanism.  If TOP plays an 
important role in the HPG axis, TOP levels would likely be subject to changes in levels of 
androgens and estrogens, the final products of the HPG axis.  Our laboratory has found that TOP 
and estrogen receptor α (ERα) are coexpressed in reproductively-relevant brain regions including 
the medial preoptic area (mPOA), arcuate nucleus (ARC), ventrolateral portion of the 
ventromedial hypothalamic nucleus (VMNvl), and the midbrain central grey (MCG)27.  Estradiol 
treatment decreases TOP levels in the VMNvl, with no differences in the other tested regions27.  
TOP activity also decreases in the VMN with estradiol treatment22.  Ovariectomized rats have 
higher levels of TOP in the anterior pituitary, and medial and lateral preoptic nuclei compared to 
non-ovariectomized rats.  Treatment with estrogen lowers activity in these regions26.   
Other studies indicate that subcutaneous injection of male mice with N-[1-(R, S)-
carboxy-3-phenylpropyl]-Ala-Aib-Tyr-p-aminobenzoate (JA-2), an inhibitor of TOP, results in 
heightened levels of testosterone in the blood (unpublished data, Tania Dhawan)28.  Because JA-
2 cannot cross the blood-brain barrier, this indicates that TOP might act locally at the level of the 
gonads, in addition to its hypothesized role in the HPG axis.  In my thesis I focus on variation in 
TOP levels in relation to estradiol concentration in prostate cancer cells.  Any effects observed, 
therefore, will not have occurred through the HPG axis, but through direct interactions between 
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TOP in Prostate Cancer 
Prostate cancer is the most common cancer in men, and the second leading cause of death 
due to cancer in the U.S.  Every year, about 240,000 men in the U.S. are diagnosed with prostate 
cancer, and about 30,000 die from it.  The overall five-year survival rate is 98%, but for men 
who are diagnosed with late-stage prostate cancer and those who have aggressive forms of the 
disease, the survival rate is only about 30%29.  Most prostate cancers are androgen-sensitive.  In 
this case, androgens act as growth factors for the cancer cells; in the presence of higher levels of 
androgens, the cells proliferate more rapidly, while in the absence of androgens, they cannot 
easily proliferate.  Because of its characteristic androgen sensitivity, this type of prostate cancer 
can be treated with androgen ablation therapy, in conjunction with other treatment methods, such 
as surgery, radiation therapy, or chemotherapy30.  As the overall survival rate indicates, these 
methods are usually very effective in eradicating the cancer.  However, if the cancer is not cured, 
yet remains exposed to the deprivation therapy for extended time periods, the therapy itself can 
lead to the cancer becoming androgen-insensitive.  Androgen-insensitive prostate cancer can no 
longer be treated with androgen ablation therapy, grows more quickly, and has higher metastatic 
potential than androgen-sensitive cancers.  This more aggressive form of prostate cancer is more 
difficult to treat, and leads to many more deaths than its androgen-sensitive counterpart.   
  The prostate epithelium consists of neuroendocrine cells that contain all the elements of 
a neural system, including neuropeptides, their receptors, and neuropeptidases.  These cells likely 
regulate growth and secretion in normal prostate31,32.  Prostatic adenocarcinomas form in the 
presence of the epithelial neuroendocrine cells of the prostate, but most likely do not develop 
from them directly, as they are post-mitotic in normal prostate.  However, it has been suggested 
that neuropeptides produced by these neuroendocrine prostate cells may act as growth factors in 
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later-stage prostate cancer in place of androgens 33.  Neuropeptides including bombesin, 
calcitonin, neurotensin, endothelin-1, and parathyroid hormone-related peptide have been shown 
to increase prostate cancer cell culture proliferation in both androgen-sensitive and androgen-
insensitive lines34-38.  
In 2004, Swanson et al. found that both TOP levels and activity were higher in androgen-
sensitive prostate cancer cells compared to those of androgen-insensitive cells.  Similarly, the 
media in which the androgen-insensitive cells were grown contained lower levels and showed 
lower activity of secreted TOP 39.  Neprilysin (neutral endopeptidase, NEP, EC3.4.24.11, 
EP24.11), a cell-surface enzyme in the same family as TOP, also cleaves a variety of bioactive 
peptides including neurotensin, endothelin-1, and bombesin 40-42.  Papandreou et al. found high 
levels of NEP in an androgen-sensitive prostate cancer cell line, and barely detectable levels of 
NEP in three androgen-insensitive lines.  NEP activity was also greatly decreased in the three 
insensitive lines43.  Results from in vivo studies supported these observations.  The 
downregulation of TOP and NEP in androgen-insensitive prostate cancer lines may be a 
mechanism by which the cells increase their rate of proliferation.  By decreasing levels of the 
enzymes that degrade certain neuropeptides, the cancer cells may be providing themselves with 
access to greater concentrations of growth factors. 
	  
PC3 and DU145 Prostate Cancer Cell Lines 
The PC3 cell line is an epithelial cell line derived from androgen-independent human 
prostatic adenocarcinoma metastasized to bone44.  Although the original PC3 cell line is 
androgen-independent, the line I use expresses AR in order to model androgen-dependent 
prostate cancer.  PC3 cells contain both Estrogen Receptor α (ERα) and ERβ, although normal 
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prostate and prostate cancer cell lines LnCAP and DU145 contain primarily ERβ45.  The DU145 
prostate cancer cell line is derived from brain metastasis and is androgen-independent.  One 
strain, like PC3-AR has been transfected with AR and responds to testosterone treatment46.  This 
androgen-sensitive strain is called DUAR, and the original androgen-insensitive strain I call 
DUT. 
 
Research Goals and Hypotheses 
We previously found that TOP immunoreactivity and activity decrease in the mouse 
ventromedial hypothalamic nucleus in response to estradiol treatment22,27.  In order to investigate 
further how TOP levels change with estradiol treatment, and thus how TOP might fit in to the 
overall regulation of estrogens and androgens, we are studying changes in TOP levels that take 
place in the prostate cancer cell lines PC3 and DU145 in response to estradiol treatment.  If TOP 
were involved in a negative feedback mechanism as part of the HPG axis, increased exposure to 
estradiol might cause TOP to be upregulated in the cells of the hypothalamus, thus allowing 
lower levels of GnRH to be released to the pituitary, resulting in a decrease in estrogen 
production.  However, TOP was downregulated in mouse hypothalamus in response to estradiol 
treatment.  Estradiol treatment of PC3 cells may help reveal the mechanisms by which TOP 
levels change.  This study could also have implications regarding the role of TOP and other 
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Materials and Methods 
 
Cell culture 
DU145 cells (DUAR and DUT) and PC3-AR cells were cultured in RPMI 1640 (Sigma S8761) 
with 10% FBS, and 0.002% sodium bicarbonate at 37°C and 5% CO2.  Cells were passaged at 
confluency, about every three to four days. 
 
Immunocytochemistry 
DU145 cells (DUAR and DUT) or PC3-AR cells were grown on Lab-Tek II CC2-treated 8-well 
glass slides in RPMI 1640 (Sigma S8761) with 10% FBS, and 0.002% sodium bicarbonate for 24 
hours.  Cells were incubated in DHT, beta-estradiol, or GnRH (10nm, 100nm, or 1.0µM) for 1 
hour, then washed with 1x PBS (phosphate-buffered saline) buffer and fixed with 4% 
paraformaldehyde for 15 minutes.  Cells were washed with 0.05M TBS (Tris-buffered saline) 
(pH 7.6), then incubated in 0.25% Triton-X for 10 minutes to improve antibody penetration.  The 
cells were blocked in 20% normal goat serum (NGS) and 1% BSA in 0.05M TBS, then 
incubated in the primary antibody to TOP, monoclonal Rabbit-anti-TOP from Marc Glucksman’s 
Lab (Rosalind Franklin University) at 1:5000 with 1% NGS and 0.5% Triton-X in 0.05M TBS 
with 0.02% sodium azide, 0.1% gelatin, and 10% Triton-X (pH 7.6) for 24 hours.  The cells were 
washed with 0.05M TBS with 0.02% sodium azide, 0.1% gelatin, and 10% Triton-X , then 
incubated in the secondary Alexa Fluor® 594 Donkey-anti-Rabbit IgG (Invitrogen cat# A21207) 
at 1:100 with 1.5% NGS in 0.05M TBS with 0.02% sodium azide, 0.1% gelatin, and 10% Triton-
X for 90 minutes, then washed with the same buffer.  The cells were incubated in nuclear stain 
DAPI at 1:106 with 1.5% NGS in 0.05M TBS with 0.02% sodium azide, 0.1% gelatin, and 10% 
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Triton-X for 30 minutes, then washed with 0.05M TBS with 0.02% sodium azide, 0.1% gelatin, 
and 10% Triton-X, then washed with 0.05 TBS. The slides were coverslipped with Gel/Mount 
(biomeda, cat# M01).  The cells were imaged for TOP and DAPI using a Leica TCS SP5 II 
confocal microscope with a 40x PLAN-APO oil objective (NA=1.25).  Alexa Fluor 594 was 
excited with a HeNe 594nm laser at 71% transmission, and emission was accepted from 605-
630nm.  DAPI was excited with a 405nm UV diode laser at 20% transmission and emission was 
accepted from 430-457nm.  Images were taken confocally at a z-depth less than 1um and 
collected at a speed of 400 pixels/sec.  Gain and offset were kept constant for each series of cells.   
 
Image Quantification 
Confocal images were quantified using Nikon NIS-Elements AR 2.30, SP4 (Build 387).  Cells 
not touching/overlapping with any neighboring cells were chosen for quantification.  All red 
intensity was recorded (no set threshold), and minimum area of a cell was set as 75µM2. 
 
Cell Lysis (Whole Cell Lysis) 
Cells were harvested and washed in 1X Phosphate Buffered Saline (PBS) solution. Cell pellets 
were immersed in 12 times their volume of RIPA lysis buffer (50 mmol/L Tris-HCl (pH 8.0), 
150 mmol/L NaCl, 1% Nonidet-P40, 0.5% deoxycholic acid and 0.1% sodium dodecyl sulfate). 
Phenylmethylsulfonyl fluoride (PMSF), a serine protease inhibitor, dissolved in isoproponal and 
a general protease inhibitor cocktail (Sigma, cat. #P2714-1BTL) were freshly added in ratios of 
1:100 to the total volume of buffer.  The cells incubated in the lysis buffer for 1 hour.  To remove 
DNA and insoluble material, cell samples were centrifuged at 13,000 rpm and 4oC for 30 
minutes. The supernatant was then harvested and stored at -80oC. 
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Cell Lysis (Cytoplasmic Fraction Separation) 
Cells were harvested and washed in 1X Phosphate Buffered Saline (PBS) solution. Cell pellets 
were immersed in 12 times their volume of Kinetic Assay Buffer (25mM TRIS Hydrochloric 
acid, 125mM KCl, 1µM zinc chloride, 10% glycerol, pH 7.8 and conductivity 12.0mS/cm2). 
Phenylmethylsulfonyl fluoride (PMSF), a serine protease inhibitor, dissolved in isoproponal and 
a general protease inhibitor cocktail (Sigma, cat. #P2714-1BTL) were freshly added in ratios of 
1:100 to the total volume of buffer. Cell pellets were kept in 70% ethyl alcohol ice slurry 
throughout the sonication process to prevent protein denaturation. Settings for sonication 
apparatus were: duty cycle set at 15 and the output control set to 1.5. Individual pulse duration 
was one second and each pellet was pulsed approximately 6 times. Sonicated cell samples were 
then centrifuged at 13,000 rpm and 4oC for 30 minutes. The supernatant (cytoplasmic fraction) 
was then harvested and stored at -80oC. 
 
Assessment of Total Protein Concentration  
Spectrophotometric analysis was used to determine the total protein concentration per 
sample.  Absorbance was set at 260 nm and 280 nm for the spectrophotometer. Each cell lysate 
sample was tested at a concentration of 1:25 in kinetic assay buffer (25mM TRIS Hydrochloric 
acid, 125mM KCl, 1µM zinc chloride, 10% glycerol, pH 7.8 and conductivity 12.0mS/cm2). 
Concentration of total protein for each sample was then calculated using the following formula: 
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Western Blotting for TOP 
(Adapted from 27)  1-20 micrograms total protein of each cell lysate sample was gel 
electrophoresed.  Samples were prepared by combining the appropriate volume of each cell 
lysate sample (calculated based on total protein concentration), 2.5 µl of 4X NuPAGE LDS 
sample buffer (Invitrogen) and 1 µl of 10X NuPAGE sample reducing agent (Invitrogen), then 
brought up to a final volume of 10 µl with water. Samples were then heated at 70°C for 5 
minutes. Proteins were separated by size on NuPAGE Novex 4-12% Bis-Tris gels (Invitrogen, 
cat. # NP0321BOX) and run at 200 V for ~35 minutes according to the manufacturer’s 
instructions. Separated proteins were then transferred onto a PVDF Immobilon-P membrane 
(Millipore), with voltage settings of 100 V for 1.5 hours. Membranes were rinsed in 0.1 M Tris-
buffered saline (TBS) with 0.05% Tween-20 (TBS-T), then blocked in TBS-T and 5% nonfat 
milk at room temperature for 1 h. Blots were cut at the 50-kDa marker. The upper blot was 
probed for TOP with a rabbit polyclonal antibody directed against rat TOP at two epitopes 
KPPAACAGD and LSKGLQVEGC 7 (dilution 1 : 20 000; generously provided by 
M. Glucksman, Rosalind Franklin University of Medicine & Science, Chicago, IL, USA), and 
the lower blot was probed for actin with a monoclonal antibody directed against the N-terminal 
peptide, Ac-Asp-Asp-Asp-Ile-Ala-Ala-Leu-Val-Ile-Asp-Asn-Gly-Ser-Gly-Lys of mouse actin 
(dilution 1 : 25 000; Chemicon International, Inc., Temecula, CA, USA) in TBS-T overnight at 
4 °C. The next day, the membranes were incubated in a horseradish peroxidase-linked donkey 
anti-rabbit secondary immunoglobulin (IgG) (dilution 1 : 10 000; GE Healthcare UK Limited, 
Chalfont St Giles, UK) or sheep anti-mouse secondary IgG (dilution 1 : 10 000; Amersham 
Biosciences, Little Chalfont, UK) for 1 h at room temperature, and proteins were detected using 
an enhanced chemiluminescence kit (ECL Plus Western Blotting Detection System; GE 
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Healthcare, Amersham Biosciences, Little Chalfont, UK - discontinued). Purified recombinant 
rat TOP protein (a gift from M. Glucksman) was run as a positive control for each Western blot.  
Immunoreactive bands were visualised using a PhosphorImager (STORM Scanner 860; 
Molecular Dynamics, Sunnyvale, CA, USA) at an excitation wavelength of 450 nm. Images of 
each gel were taken and saved as 16-bit grayscale Tiff files and the area of each immunoreactive 
band was analysed using IMAGEQUANT, version 5.0 (GE Healthcare). TOP levels were 
normalized to actin. 
 
Quenched Fluorescence Assay 
TOP activity assays were conducted with a SpectraMax M3 Microplate Reader with SoftMax 
Pro microplate data acquisition software. Total volume for each sample was 200 uL in kinetic 
assay buffer (25mM TRIS Hydrochloric acid, 125mM KCl, 1µM zinc chloride, 10% glycerol, 
pH 7.8 and conductivity 12.0mS/cm2) including 5ug total protein and 1uL of substrate. Reaction 
was monitored for 20 min at room temperature. The substrate for TOP was 7-methoxycoumarin-
4-acetylPro-Leu-Gly-Pro-Lys-dinitrophenol (MCA), 1.4 mM stock solution. Settings for the 
TOP assay were: emission wavelength, 405 nm; excitation wavelength, 320 nm. Reaction was 
carried out in the presence or absence of a specific inhibitor of TOP, cFPAAF-pAB (N-[1-(R,S)-
carboxy-3-phenylpropyl]-Ala-Ala-Phe-pAB (cFP), 16.5 M. The slope of the graph 
(fluorescence/second) was then used to determine the activity of TOP. The activity from samples 
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Statistical Analysis 
JMP Pro 9.0 (SAS Institute Inc.) was used for all statistical analyses. All pairs of means were 
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Results 
 
In order to determine if TOP plays a role in steroid hormone regulation, we investigated 
the effects of hormone treatments on TOP levels and localization in prostate cancer cells.  
Initially, I explored the effects of hormone treatment through immunocytochemistry (ICC) and 
imaging of DU145 cells in culture. DU145 cells are obtained from brain metastasis and are 
androgen-insensitive.  However, I used a strain of DU145 transfected with functional androgen 
receptor (designated DUAR), as well as the original insensitive strain (DUT).  
 
Verification of Staining Specificity 
To confirm that the antibody against TOP is specific for TOP, the antibody was incubated 
with 80x purified TOP protein for 24 hours before incubating with the cells during ICC.  With 
the antibody already bound to TOP, it should not bind to cellular TOP, but instead remain in 
solution to be removed during washing steps.  This leaves no binding site for the secondary 
antibody, and it too is removed.  In the absence of the fluorophore on the secondary antibody, no 
fluorescence should be detected during imaging.  If the TOP antibody binds only TOP, there 
should be no staining of the cells incubated with preabsorbed TOP antibody.   
The DU145 cells incubated with the preabsorbed antibody showed highly reduced 
fluorescence in comparison to the cells treated with non-preabsorbed TOP antibody (Fig. 2).  
This result indicates that the antibody primarily binds TOP.  The residual staining could be due 
to TOP antibody binding with lower affinity to a TOP-like protein in the cells, or to non-specific 
binding of the secondary antibody. 
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Figure 2.  TOP antibody preabsorption with wildtype TOP results in highly reduced TOP 
staining in androgen-sensitive DU145 cells.  TOP antibody was incubated in 80x wildtype TOP 
for 24 hours before being incubated with the prostate cancer cells.  The cells were then 
incubated with a secondary antibody, which produces the red staining in the images above.  
When imaged, the cells incubated with the preabsorbed antibody showed highly reduced 
fluorescence in comparison to the cells treated with non-preabsorbed TOP antibody.  This result 
indicates that the antibody primarily binds TOP. (Representative cells shown.) 
 
Immunocytochemical Analysis of Hormone Treatment on TOP Levels 
 In order to investigate the effects of hormone treatment on TOP levels, both DUAR and 
DUT cells were incubated in 10nM DHT, estradiol, and GnRH for 1 hour, immunostained for 
TOP and imaged.  TOP staining per cell was quantified (Fig. 3a,b).  Estradiol and GnRH 
appeared to cause a rise in overall TOP levels in both androgen-sensitive and insensitive cells, 
while there was no change with DHT treatment in androgen-insensitive cells, and a slight rise 
due to DHT in androgen-sensitive cells.  Repetition of this experiment in androgen-sensitive 
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cells yielded a similar relationship between levels of TOP due to treatment with the three 
hormones, but the control cells had a much higher relative TOP intensity than in the initial 
experiment (Fig. 3c).  However, the sample sizes in this repeated experiment were much smaller 
than the initial experiment due to difficulty quantifying the cells, and differences in TOP staining 
between treatment groups were not significant. 
	  
Figure 3. Estradiol and GnRH treatment raise levels of TOP in androgen-sensitive and 
androgen-insensitive prostate cancer cells.  Androgen-insensitive (DUT) and androgen-
sensitive (DUAR) DU145 cells were incubated in 10nM DHT, estradiol, or GnRH for one hour, 
then immunostained for TOP and imaged. (a) Quantification of TOP staining in androgen-
insensitive (DUT) cells after hormone treatment. *P<0.05 ethanol control, n=13; DHT, n=60; 
estradiol, n=35; GnRH, n=14 (b) Quantification of TOP staining in androgen-sensitive (DUAR) 
cells after hormone treatment. * and **P<0.05 compared to ethanol control and DHT. Ethanol 
control, n=68; DHT, n=63; estradiol, n=40; GnRH, n=13. (c) Repetition of experiment in (b); 
Quantification of TOP staining in androgen-sensitive (DUAR) cells after hormone treatment.  No 
significant differences in TOP staining.  Ethanol control, n=5; DHT, n=5; estradiol, n=4; 
GnRH, n=5.  Error bars indicate standard error. 
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DHT and estradiol appear to have different effects on TOP levels in DU145 cells, with 
DHT causing little change and estradiol producing an increase in total TOP levels.  In order to 
further explore the effects of these steroid hormones on TOP levels, DUT and DUAR cells were 
incubated with DHT, estradiol, and a combination of estradiol and DHT (Fig. 4a).  As before, 
DUT cells treated with DHT did not show a change in TOP levels, while cells treated with 
estradiol showed increased TOP levels.  However, combined estradiol and DHT treatment 
resulted in TOP dropping to levels similar to the control and DHT treatment group.  Treated 
DUAR cells all show increased TOP levels compared to the ethanol control cells (the control 
cells were not detectable), but unlike the DUT cells, TOP levels are just as high when cells are 




Figure 4. While estradiol treatment increases TOP levels, levels after combined estradiol and 
DHT treatment are similar to DHT-only treatment in DUT cells.  Androgen-insensitive (DUT) 
and androgen-sensitive (DUAR) DU145 cells were incubated in 1.0uM DHT, estradiol, or 1.0uM 
DHT and 1.0uM estradiol for one hour, then immunostained for TOP and imaged confocally. (a) 
Quantification of TOP staining in androgen-insensitive cells after hormone treatment. *P<0.05 
ethanol control, n=8; DHT, n=9; estradiol, n=8; estradiol and DHT, n=7. (b) Quantification of 
TOP staining in androgen-sensitive cells after hormone treatment.  Staining of control cells was 
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too faint to be measured.  Differences are not significant.  DHT, n=16; estradiol, n=5; estradiol 
and DHT, n=11.  Error bars indicate standard error. 
 
Dose-Dependent Estradiol Response 
Estradiol incubation appears to have a significant effect on TOP levels in DU145 cells.  
In order to further explore these effects, DUAR and DUT cells were incubated in increasing 
concentrations of estradiol to determine if there is a dose-dependent effect on TOP levels and 
localization.  Although total TOP levels still rise with estradiol incubation, in DUT cells nuclear 
TOP levels in particular appeared to increase with increasing estradiol concentration (Fig. 5a).  
Quantification of nuclear TOP corroborates this observation (Fig. 5b). 
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Figure 5.  TOP localizes to nuclei in androgen-insensitive (DUT) prostate cancer cells with 
estradiol incubation.  DUT cells were incubated with increasing concentrations of estradiol for 
one hour, then immunostained for TOP and imaged confocally.  (a) Representative cells shown.  
Scale bars are 10um. (b) Quantification of nuclear TOP staining.  Differences not significant.  
Ethanol control, n=5; 0.01uM estradiol, n=3; 0.1uM estradiol, n=6; 1.0uM estradiol, n=5.	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Western Analysis of Estradiol Treatment on TOP levels 
 Quantifying TOP levels through imaging is not ideal since it can be subjective: the 
demands of using the imaging software make it difficult to quantify large numbers of cells - they 
must not touch other cells in order to be correctly analyzed- and many variables such as 
application of the coverslip can affect the intensity of the image.  We therefore moved to 
quantifying TOP levels using Western blot.  We also were unsure if the DUT and DUAR cell 
lines were clearly androgen-insensitive and androgen-sensitive, respectively, so we began using 
the PC3 prostate cancer line.  PC3 cells are derived from bone metastasis and are originally 
androgen-insensitive, although we use a line of PC3 cells that has been transfected with 
androgen receptor, and should thus be androgen-sensitive.  We verified that the PC3-AR line 
does proliferate more rapidly when incubated in DHT than do PC3 cells (Michelle Brann, 
unpublished data). 
 PC3 cells now were incubated in estradiol at different concentrations, either for 1 or 24 
hours.  Cells were lysed, and lysates were separated by electrophoresis, then blotted and 
immunostained for TOP and actin.  TOP bands were quantified and normalized to actin bands 
(Fig. 6).  TOP band intensities fluctuated slightly, but generally remained at a constant intensity 
and showed no clear trend in relation to estradiol incubation.  Data collection was made difficult 
by the apparent non-specificity of the TOP antibody.  Multiple bands were detected by the TOP 
antibody across a range of molecular weights, yet background remained low (Fig. 7). 
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Figure 6.  Western analysis reveals no change in intracellular TOP levels with estradiol 
incubation.  Cells were incubated with 0M, 100pM, 1.0nM, and 100nM estradiol for either 1 or 
24 hours, then lysates were separated by electrophoresis and immunostained for TOP and actin. 
(a)(c) Resulting Western blots. (b)(d)Quantification of TOP normalized to actin. 
	   28 
 
Figure 7. TOP detection in Western analysis.  TOP bands shown in red box.  Actin bands 
shown in yellow box. (a) and (b) correspond to Fig. 6 (a) and (c). 
 
TOP Activity Analysis after Estradiol Treatment 
 Cytoplasmic TOP Activity in PC3-AR cells was measured after treatment with estradiol 
for 1 or 24 hours.  Cells treated with estradiol for 1 or 24 hours showed decreased TOP activity 
in cytoplasm compared to cells treated with no estradiol (Fig. 8).  Although TOP activity does 
not necessarily correlate with TOP levels, this result may make sense if TOP is moving to nuclei, 
causing a decrease in cytoplasmic TOP levels (Fig. 5). 
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Figure 8. TOP activity in prostate cancer cell cytoplasm decreases with estradiol 
treatment.  PC3-AR cells were treated with three concentrations of estradiol (100pM, 1.0nM, 
100nM) for 1 (yellow) or 24 (green) hours.  TOP activity in the cytoplasmic fraction of each 
treatment group was evaluated using a quenched fluorescence activity assay.  The buffer the 
samples were diluted in served as a control and showed almost no activity.  Purified TOP and 
cells treated with no estradiol had significant TOP activity.  Cells treated with all three 




Overall, imaging studies suggested that estradiol incubation increases TOP levels in both 
androgen-sensitive and androgen-insensitive prostate cancer cells and increased localization to 
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Discussion 
 
In order to determine whether or not, and in what way, hormone treatment affects TOP 
levels and localization, prostate cancer cells were incubated in DHT, estradiol and GnRH, 
immunostained for TOP and imaged.  Image quantification suggested that estradiol incubation 
increased TOP levels in prostate cancer cells.  Although image quantification can be highly 
variable and sample sizes were generally very small, the jump in TOP levels with estradiol 
treatment compared to untreated cells was fairly consistent (Fig. 3a-b, 4).  Although this 
relationship between control and estradiol-treated cells was not observed in a repeat of the initial 
hormone incubation experiment (Fig. 3c), these results were not significantly different and 
consisted of very small sample sizes.  Interestingly, the relationship among TOP levels in cells 
treated with the three hormones remained similar.  DHT-treated cells generally display TOP 
levels similar to untreated cells (Fig. 3a-b, 4), and always lower than estradiol-treated cells (Fig. 
3, 4).  Although we believed the DUT cell line was androgen-insensitive and the DUAR line was 
androgen-sensitive, DHT-treated cells had similar levels of TOP in both cell lines, compared to 
the control.  GnRH treatment produced TOP levels similar to estradiol treatment in both cell 
lines.  Imaging results also indicated that TOP levels increased in nuclei in DUT (androgen-
insensitive cells) with estradiol treatment. 
Since estradiol treatment affects TOP levels in certain regions of the mouse brain27, we 
focused on TOP level changes due to estradiol treatment.  To further study the effects of 
estradiol, we measured TOP levels in estradiol-treated prostate cancer cells by Western 
immunoblot.  This method should be more reliable than image quantification since it involves 
less variation in detection and measures the TOP contents of thousands of cells rather than the 
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few whose TOP staining can be measured.  However, TOP detection proved to be more 
complicated than expected as immunostained elecrophoresis-separated whole cell lysates 
displayed multiple bands detected by the antibody to TOP (Fig. 7).  The bands quantified were 
closest in molecular weight to the purified TOP band.  The results of these experiments indicated 
that TOP levels change very little, or fluctuate slightly in PC3-AR (androgen-sensitive) prostate 
cancer cells treated with estradiol (Fig. 6).   
Overall, the quantified imaging results indicated that estradiol treatment may cause total 
TOP levels to increase in both androgen-sensitive and androgen-insensitive prostate cancer cells, 
and nuclear TOP levels to increase, but Western results suggested that estradiol treatment has 
little effect on cellular TOP levels in androgen-sensitive cells.  It is possible that the conflicting 
results are a consequence of using two different cell lines for the imaging and Western 
experiments.  Although the two lines are both prostate cancer cells, they do originate from 
different individuals and the DU145 cells contain primarily ERβ while the PC3 line contains 
both ERα and ERβ45.  DU145 cells might therefore respond to estradiol treatment differently 
than PC3 cells.   
Males produce estrogens in the testis and brain47.  Estrogens and both ERα and ERβ play  
roles in the development and function of the male reproductive system48.  The two estrogen 
receptors bind estradiol with equal affinity, but have different functions and different tissue 
distruibution49.  ER knockout mice have been used to study the roles of ERα and ERβ in the male 
reproductive system: knockout of ERα results in reduced male fertility through dilution of sperm 
and disrupted sperm morphology50, and knockout of ERβ does not reduce fertility, but does 
result in increased aggressive behavior48,51,52.  At the level of prostate cancer, ERβ is thought to 
protect against uncontrolled cell proliferation and to be downregulated as prostate cancer 
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progresses53-55.  In contrast, ERα promotes proliferation, so estrogens can have both beneficial 
and harmful effects in prostate cancer56.  Thus presence of different levels of the two estrogen 
receptors may contribute to differences in behavior of the PC3 and DU145 cell lines. 
Previous studies found that estradiol treatment of ovariectomized female mice lowers 
TOP levels and activity in reproductively relevant regions of the brain26,27.  This effect is 
opposite to the one we found from imaging results, in which estradiol treatment raised TOP 
levels.  However, our result was obtained in cell culture with human prostate cancer cells while 
TOP level lowering was observed in female mice.  Aside from responsiveness to steroid 
hormones, the two systems have little in common.  It is possible that estradiol has a different, or 
no local effect on TOP levels while still having this TOP lowering effect in vivo.  The fact that 
nuclear TOP appears to increase with estradiol treatment, whether or not total cellular TOP 
increases, indicates that estradiol can have a direct effect on the cells. 
Nuclear TOP appears to increase with 1 hour estradiol incubation.  Although TOP’s 
purpose in the nucleus is not known – most of its substrates are extracellular – localization to the 
nucleus has been observed multiple times, especially in the brain, where it is primarily 
nuclear6,7,57.  TOP contains a possible nuclear localization sequence (PETRRKV) at residues 
234-240, although its presence in a helix makes the sequence less likely to be involved in nuclear 
transport58.  While TOP is localized mostly to the nuclei in neurons, neurolysin, a closely related 
metallopeptidase with similar structure, is localized almost exclusively to the cytoplasm, and 
more often found on the extracellular surface of the plasma membrane than TOP7,57,58.  This 
seems to suggest that TOP has an important role in the nucleus, while neurolysin is more suited 
to processing signaling peptides.  However, unlike in brain, the current results show that TOP is 
often more concentrated in the cytoplasm than in the nucleus in prostate cancer cells (Fig. 2, 5).  
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If the imaging results are correct, and estradiol treatment does cause a rise in TOP levels, 
this might be detrimental to the prostate cancer cells.  As Swanson et. al hypothesized, TOP may 
degrade growth factors of prostate cancer, and it is downregulated in androgen-insensitive 
prostate cancer cells, which rely solely on these growth factors39.  If TOP is upregulated by 
estradiol treatment, prostate cancer cells may grow less rapidly due to decreased access to 
growth factors.  Castagnetta et. al found that estradiol treatment causes increased proliferation of 
LNCaP (androgen-sensitive) prostate cancer cells59.  However, estradiol treatment of androgen-
insensitive PC3 cells and castrate resistant prostate cancer in mice by Carruba et. al and 
Montgomery et. al respectively, inhibited growth60,61.  Administration of estrogens to prostate 
cancer patients also inhibits cancer growth, and estrogenic drugs were used to treat prostate 
cancer for 25 years.  However, this treatment relies on the presence of the HPG axis: estrogens or 
estrogen-like drugs inhibit the release of gonadotropins, preventing production of testosterone 
and therefore deprive androgen-sensitive prostate cancer of androgens62.  If estradiol treatment 
does upregulate TOP in androgen-insensitive prostate cancer cells, this mechanism could play a 
role in inhibiting prostate cancer growth. 
Future studies should optimize use of the TOP antibody with PC3 cell lysates in Western 
blots to confirm if there is or is not an effect on TOP levels with estradiol incubation.  If there is 
indeed a change, it would be useful to investigate the mechanism by which the change occurs: by 
an increase or decrease in rate of protein degradation/translation.  Similar experiments could also 
be carried out with DHT incubation of prostate cancer cells.  DHT treatment may cause similar 
changes in TOP levels to estradiol treatment, since both are end products of the HPG axis.  
However, results up to this point indicate that their effects may not be similar with direct 
incubation. 
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Although the current study was inconclusive, some results suggest that TOP levels may 
increase overall and particularly in the nucleus in estradiol-treated prostate cancer cells.  This 
suggests that the products of the HPG axis affect TOP levels, which indicates TOP may play a 
role in this system.  An increase in TOP levels in androgen-insensitive prostate cancer cells may 
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